Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Product ID

Click to order products descending

Display 15 Products per page

Yescarta
Read More
Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.
January 30, 2019
Find out more
Kymriah
Read More
Kymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment that binds CD19 and is linked to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta.
January 31, 2019
Find out more
MEDI8897
Read More
MEDI8897 is a human immunoglobulin G1 MAb derived from human B cells intended to provide protection against RSV infection.
October 5, 2018
Find out more
RSV preF vaccine
Read More
Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.
October 5, 2018
Find out more
Symdeko
Read More
Vertex’s Symdeko ([tezacaftor + ivacaftor]) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector compound
September 3, 2018
Find out more
Seribantumab
Read More
Seribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3).
August 30, 2018
Find out more
Lorlatinib
Read More
Lorlatinib (Pfizer) is an orally administered anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor (TKI) with potential antineoplastic activity
August 30, 2018
Find out more
Entrectinib
Read More
Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
August 30, 2018
Find out more
Cemiplimab
Read More
Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody
August 30, 2018
Find out more
Capmatinib
Read More
Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR).
August 30, 2018
Find out more
Alunbrig
Read More
Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
September 8, 2018
Find out more
Ygalo
Read More
Ygalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine
August 9, 2018
Find out more
Isatuximab
Read More
Isatuximab (Sanofi/ImmunoGen) is a humanized monoclonal antibody which targets cancer cells expressing the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma (MM) cells, but at low levels in other tissues.
August 9, 2018
Find out more
bb2121
Read More
Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.
August 9, 2018
Find out more
Alofisel
Read More
Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.
August 2, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *